Clinical context: Human growth hormone itself is well-documented for body composition improvement. / operates by optimizing the body's own GH secretion rather than replacing it, which is both safer and more physiologically appropriate. Clinical trials specifically on / are limited, but GH secretagogue research broadly supports the metabolic rationale.
is an FDA-approved GHRH analog specifically indicated for visceral adipose tissue reduction in HIV-associated lipodystrophy. It is among the most well-studied GHRH analogs in humans for body composition effects.
A clinical trial published in the New England Journal of Medicine (2010) found that reduced visceral fat by an average of 18% versus 5% for placebo over 26 weeks. Critically, it specifically targeted visceral fat — the most metabolically dangerous depot — while preserving lean mass.
In clinical practice, is increasingly used off-label for visceral body composition changes in metabolically compromised patients and those with growth hormone deficiency. It is one of the most evidence-backed peptides specifically for abdominal body composition changes.
AOD-9604 (Advanced Obesity Drug 9604) is a modified fragment of human growth hormone — specifically the C-terminal fragment (hGH176-191) believed to be responsible for GH's lipolytic (fat-burning) effects without the anabolic or IGF-1-stimulating effects of full GH.
The mechanism: AOD-9604 activates beta-3 adrenergic receptors in fat cells, stimulating fat cell breakdown (lipolysis) and reducing fat cell differentiation (lipogenesis). Animal studies demonstrated significant reductions in body fat without the blood glucose or IGF-1 effects seen with full HGH.
Human clinical trials for obesity were conducted in the early 2000s (Phase 2/3) and showed modest weight loss effects (~1 kg over 12 weeks at optimal dosing) — meaningful statistically but modest clinically. AOD-9604 received GRAS (Generally Recognized As Safe) status from the FDA in 2014. Current use is primarily as a complementary peptide in multi-peptide protocols rather than standalone therapy.
This peptide is a synthetic pentadecapeptide derived from a protein found in gastric juice. It is primarily recognized for its remarkable tissue regeneration and wellness-supporting properties, but its metabolic relevance is emerging.
's metabolic contributions to weight loss programs are indirect but meaningful.
Evidence is primarily preclinical (animal models show impressive recovery support and anti-inflammatory effects). Human clinical trials are limited but ongoing. In practice, is often stacked with GLP-1 medications or / to enhance tolerability and recovery outcomes.
| Peptide | Mechanism | Avg. Weight Loss | Evidence Level | Best For |
|---|---|---|---|---|
| Semaglutide | GLP-1 agonist | 14–16% | Tier 1 (FDA-approved) | Obesity, overweight + comorbidities |
| Tirzepatide | GLP-1 + GIP agonist | 20–22% | Tier 1 (FDA-approved) | Maximum weight loss, T2D + obesity |
| GHRH analog | ~18% visceral fat | Tier 2 (FDA-approved, off-label use) | Visceral fat, GH deficiency | |
| / | GH secretagogue stack | Variable (supports body recomp) | Tier 2 (mechanistic/clinical) | Body recomposition, recovery, sleep |
| AOD-9604 | GH fragment / lipolysis | Modest (~1 kg) | Tier 3 (Phase 2/3 human trials) | Adjunct fat-burning support |
| Anti-inflammatory / repair | Indirect | Tier 3 (primarily preclinical) | Recovery, GI support, adjunct use |
In clinical practice, peptides are rarely used in isolation. A licensed provider experienced in peptide therapy will assess your labs (including IGF-1, fasting insulin, metabolic panel, and hormone levels), goals, and medical history to design a protocol that addresses your specific metabolic bottlenecks.
Common evidence-informed combinations include.
Even the most potent peptide protocols work best in the context of fundamental metabolic health practices.
Truventa Medical's physicians specialize in evidence-based peptide therapy for weight loss and body recomposition. We evaluate your labs, symptoms, and goals to design a protocol that makes clinical sense for you — not a one-size-fits-all approach. Start with a consultation today.
Start Your Consultation